Revenue
No reported data
Dyne Therapeutics, Inc. (DYN)
Price—Loading quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Research & development | $398.3M | $281.4M | $210.8M | $142.8M | $121.3M | $45.2M | $11.0M |
| Operating expenses | $468.2M | $343.9M | $242.2M | $171.0M | $150.0M | $58.6M | $13.8M |
| Operating income | −$468.2M | −$343.9M | −$242.2M | −$171.0M | −$150.0M | −$58.6M | −$13.8M |
| EBITDAderived | −$466.1M | −$342.2M | −$240.5M | −$169.3M | −$148.9M | −$57.9M | −$13.6M |
| Net income | −$446.2M | −$317.4M | −$235.9M | −$168.1M | −$149.3M | −$59.4M | −$14.9M |
| Basic EPSper diluted share | -$3.47 | -$3.37 | -$3.95 | -$3.23 | -$2.93 | -$4.13 | -$6.08 |
| Diluted EPSper diluted share | -$3.47 | -$3.37 | -$3.95 | -$3.23 | -$2.93 | -$4.13 | -$6.08 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 29, 2026Form 4 · 10b5-1 | Rhodes Jason PDirector | SellCommon Stock · indirect | 40.7K | $21.14 | $860.4K | 975.9K |
| Jun 29, 2026Form 4 · 10b5-1 | Rhodes Jason PDirector | SellCommon Stock · indirect | 51.8K | $21.14 | $1.09M | 1.34M |
| Jun 29, 2026Form 4 · 10b5-1 | Rhodes Jason PDirector | SellCommon Stock · indirect | 103.0K | $21.14 | $2.18M | 4.48M |
| Jun 26, 2026Form 4 · 10b5-1 | Rhodes Jason PDirector | SellCommon Stock · indirect | 64.4K | $21.28 | $1.37M | 1.02M |
| Jun 26, 2026Form 4 · 10b5-1 | Rhodes Jason PDirector | SellCommon Stock · indirect | 81.9K | $21.28 | $1.74M | 1.40M |